Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject

被引:24
作者
Marchei, E. [1 ]
Farre, M. [2 ,3 ]
Pellegrini, M. [1 ]
Garcia-Algar, O. [4 ]
Vall, O. [4 ]
Pacifici, R. [1 ]
Pichini, S. [1 ]
机构
[1] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy
[2] Hosp del Mar, IMIM, Bioanal & Analyt Serv Res Grp, Neuropsychopharmacol Program, Barcelona, Spain
[3] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[4] Hosp del Mar, IMIM, URIE, Paediat Serv, Barcelona, Spain
关键词
Methylphenidate pediatrics oral fluid; Sweat; CHROMATOGRAPHY-MASS SPECTROMETRY; SALIVA; DRUGS; PLASMA; ABUSE; HAIR;
D O I
10.1016/j.forsciint.2009.12.038
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
Methylphenidate (MPH) is a stimulant medication widely used for treating attention-deficit hyperactivity disorder (ADHD) in children and adolescents. Therapeutic monitoring for this drug is essentially lacking and alternative biological matrices, such as oral fluid and sweat, should be investigated for noninvasive assessment of short- and long-term history of drug use. We report the excretion pro. le of MHP and its metabolite ritalinic acid (RA) in oral fluid and sweat from a 12-year-old boy treated with the extended release drug formulation. Concentrations of MPH and RA in oral fluid, sweat and plasma were measured by liquid chromatography-mass spectrometry. Oral fluid-to-plasma ratio at each time interval was calculated at the start of the treatment and correlated with salivary pH. Excretion of MPH in sweat patches, collected up to 24 h with PharmChek patches was also investigated. MPH and RA were both detected in oral fluid with a pharmacokinetic profile similar to that in plasma. Oral fluid peak concentrations of MPH ranged between 13.5 and 30.9 ng/mL at 3.0 h after drug intake. Oral fluid-to-plasma MPH ratio between 13.1 and 3.2 demonstrated an accumulation of the drug in oral fluid. Conversely, RA was found in oral fluid at peak concentration (23.4-62.9 ng/mL) equivalent to one-tenth of those found in plasma. Concentration profiles of MPH and RA in oral fluid were quite constant during the four weeks of drug administration. In sweat, MPH was detected for the first time at 5 h after drug administration (range: 9.3-11.2 ng/patch) up to 24 h (range: 29.8-38.7 ng/patch). RA was not detected in the sweat patches during the 24 h time of collection. The results suggest that measurement of MPH in oral fluid can be used as a potential alternative to drug monitoring in plasma. Moreover, MPH measurement in sweat patches can be used for noninvasive monitoring of MPH consumption andmisuse in situations where detection of recent abuse is of interest. (C) 2010 Published by Elsevier Ireland Ltd.
引用
收藏
页码:59 / 63
页数:5
相关论文
共 20 条
[1]   Clinical pharmacokinetics of amfetamine and related substances -: Monitoring in conventional and non-conventional matrices [J].
de la Torre, R ;
Farré, M ;
Navarro, M ;
Pacifici, R ;
Zuccaro, P ;
Pichini, S .
CLINICAL PHARMACOKINETICS, 2004, 43 (03) :157-185
[2]   An overview of the use of urine, hair, sweat and saliva to detect drug use [J].
Dolan, K ;
Rouen, D ;
Kimber, J .
DRUG AND ALCOHOL REVIEW, 2004, 23 (02) :213-217
[3]   Review: Pharmacokinetics of illicit drugs in oral fluid [J].
Drummer, OH .
FORENSIC SCIENCE INTERNATIONAL, 2005, 150 (2-3) :133-142
[4]   Characteristics and motives of college students who engage in nonmedical use of methylphenidate [J].
DuPont, Robert L. ;
Coleman, John J. ;
Bucher, Richard H. ;
Wilford, Bonnie B. .
AMERICAN JOURNAL ON ADDICTIONS, 2008, 17 (03) :167-171
[5]   Urinary screening for methylphenidate (Ritalin) abuse: a comparison of liquid chromatography-tandem mass spectrometry, gas chromatography-mass spectrometry, and immunoassay methods [J].
Eichhorst, J ;
Etter, M ;
Lepage, J ;
Lehotay, DC .
CLINICAL BIOCHEMISTRY, 2004, 37 (03) :175-183
[6]   The role of alternative specimens in toxicological analysis [J].
Gallardo, E. ;
Queiroz, J. A. .
BIOMEDICAL CHROMATOGRAPHY, 2008, 22 (08) :795-821
[7]  
GREENHILL LL, 1987, PSYCHOPHARMACOL BULL, V23, P115
[8]  
HORNING MG, 1977, CLIN CHEM, V23, P157
[9]   Pharmacokinetics and clinical effectiveness of methylphenidate [J].
Kimko, HC ;
Cross, JT ;
Abernethy, DR .
CLINICAL PHARMACOKINETICS, 1999, 37 (06) :457-470
[10]   Enantioselective gas chromatography-negative ion chemical ionization mass spectrometry for methylphenidate in human plasma [J].
Lin, SN ;
Andrenyak, DM ;
Moody, DE ;
Foltz, RL .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1999, 23 (06) :524-530